A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Madrid, Peter B ^a   Chopra, Sidharth ^a,e   Manger, Ian D ^a,f   Gilfillan, Lynne ^a   Keepers, Tiffany R ^a,g   Shurtleff, Amy C ^a,d   Green, Carol E ^a   Iyer, Lalitha V ^a   Dilks, Holli Hutcheson ^a,h   Davey, Robert A ^b,c   Kolokoltsov, Andrey A ^b   Carrion, Ricardo ^c   Patterson, Jean L ^c   Bavari, Sina ^d   Panchal, Rekha G ^d   Warren, Travis K ^d   Wells, Jay B ^d   Moos, Walter H ^a   Burke, RaeLyn L ^a   Tanga, Mary J ^a  

^a SRI INTERNATIONAL   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e CENTRAL DRUG RESEARCH INSTITUTE   (India)

^f Synbody Biotechnology Inc ^*  (United States)

^g Wiss Janney Elstner Associates Inc   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMODIAQUINE; BAFILOMYCIN A1; BIPERIDEN; CARPROFEN; CHLOROQUINE; CINCHOCAINE; CIPROFLOXACIN; CLARITHROMYCIN; DEXBROMPHENIRAMINE; DIPHENOXYLATE; DIPHENYLPYRALINE; DIPIVEFRINE; DIRITHROMYCIN; ERYTHROMYCIN; ESTRADIOL; FLUOXETINE; KETOTIFEN; LEVOPROPOXYPHENE; LOMEFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; OXYPHENCYCLIMINE; PAROXETINE; PENBUTOLOL; PROCHLORPERAZINE; PROTRIPTYLINE; TOREMIFENE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; COXIELLA BURNETII; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; FOOD AND DRUG ADMINISTRATION; FRANCISELLA TULARENSIS; LASSA FEVER; LASSA VIRUS; MALE; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OFF LABEL DRUG USE; TREATMENT RESPONSE; VIRUS ENTRY;

EID: 84875965830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060579     Document Type: Article

References (48)

1. Kuhn JH, Dodd LE, Wahl-Jensen V, Radoshitzky SR, Bavari S, et al. (2011) Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror 9: 361-371.
2. Center for Disease Control and Prevention (2013) Bioterrorism Agents/Diseases. Center for Disease Control and Prevention. Available: http://www.bt.cdc.gov/agent/agentlist-category.asp: Accessed 10 Feb 2013.
3. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, et al. (2002) Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 287: 2236-2252.
4. Center for Disease Control and Prevention (2012) Anthrax. Available: http://emergency.cdc.gov/agent/anthrax/: Accessed 29 Feb 2012.
5. Ellis J, Oyston PC, Green M, Titball RW, (2002) Tularemia. Clin Microbiol Rev 15: 631-646.
6. Center for Disease Control and Prevention (2012) Tularemia. Available: http://emergency.cdc.gov/agent/tularemia/: Accessed 29 Feb 2012.
7. Tigertt WD, Benenson AS, Gochenour WS, (1961) AIRBORNE Q FEVER. Bacteriological Reviews 25: 285-293.
8. Madariaga MG, Rezai K, Trenholme GM, Weinstein RA, (2003) Q fever: a biological weapon in your backyard. Lancet Infect Dis 3: 709-721.
9. Johnson E, Jaax N, White J, Jahrling P, (1995) Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76: 227-236.
10. Center for Disease Control and Prevention (2012) Viral Hemorrhagic Fevers. Available: http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm: Accessed 29 Feb 2012.
11. Aronson JK, (2007) Old drugs-new uses. Br J Clin Pharmacol 64: 563-565.
12. Chong CR, Sullivan DJ Jr, (2007) New uses for old drugs. Nature 448: 645-646.
13. Ashburn TT, Thor KB, (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683.
14. Boguski MS, Mandl KD, Sukhatme VP, (2009) Drug discovery. Repurposing with a difference. Science 324: 1394-1395.
15. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 103: 11473-11478.
16. U.S. Food and Drug Administration (2010) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD: U.S. FDA.
17. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R, (2003) Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 3: 722-727.
18. Savarino A, Cauda R, Cassone A, (2007) On the use of chloroquine for chikungunya. Lancet Infect Dis 7: 633.
19. Rolain JM, Colson P, Raoult D, (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30: 297-308.
20. Acosta EG, Bruttomesso AC, Bisceglia JA, Wachsman MB, Galagovsky LR, et al. (2008) Dehydroepiandrosterone, epiandrosterone and synthetic derivatives inhibit Junin virus replication in vitro. Virus Res 135: 203-212.
21. De D, Krogstad FM, Byers LD, Krogstad DJ, (1998) Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem 41: 4918-4926.
22. Saeed MF, Kolokoltsov AA, Davey RA, (2006) Novel, rapid assay for measuring entry of diverse enveloped viruses, including HIV and rabies. J Virol Methods 135: 143-150.
23. Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, et al. (2007) Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J 4: 39.
24. Savarino A, Gennero L, Chen HC, Serrano D, Malavasi F, et al. (2001) Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 15: 2221-2229.
25. Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, et al. (2004) Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 35: 223-232.
26. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, et al. (2009) The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 83: 2883-2891.
27. Schornberg KL, Shoemaker CJ, Dube D, Abshire MY, Delos SE, et al. (2009) Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A 106: 8003-8008.
28. Marzi A, Moller P, Hanna SL, Harrer T, Eisemann J, et al. (2007) Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 196Suppl 2: S237-246.
29. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, et al. (2008) Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 294: F1050-1058.
30. Vigerust DJ, McCullers JA, (2007) Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses 1: 189-192.
31. Freiberg AN, Worthy MN, Lee B, Holbrook MR, (2010) Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 91: 765-772.
32. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, et al. (2009) Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol 83: 11979-11982.
33. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, et al. (2008) On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 8: 837-839.
34. De Lamballerie X, Ninove L, Charrel RN, (2009) Antiviral treatment of chikungunya virus infection. Infect Disord Drug Targets 9: 101-104.
35. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, et al. (2010) A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4: e785.
36. Kadir F, Eling WM, Abrahams D, Zuidema J, Crommelin DJ, (1992) Tissue reaction after intramuscular injection of liposomes in mice. Int J Clin Pharmacol Ther Toxicol 30: 374-382.
37. Peeters PA, Brunink BG, Eling WM, Crommelin DJ, (1989) Therapeutic effect of chloroquine(CQ)-containing immunoliposomes in rats infected with Plasmodium berghei parasitized mouse red blood cells: comparison with combinations of antibodies and CQ or liposomal CQ. Biochim Biophys Acta 981: 269-276.
38. Peeters PA, Huiskamp CW, Eling WM, Crommelin DJ, (1989) Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology 98 Pt 3: 381-386.
39. Titulaer HA, Eling WM, Crommelin DJ, Peeters PA, Zuidema J, (1990) The parenteral controlled release of liposome encapsulated chloroquine in mice. J Pharm Pharmacol 42: 529-532.
40. Egan TJ, (2001) Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials. Mini Rev Med Chem 1: 113-123.
41. O'Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, et al. (2003) Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem 46: 4933-4945.
42. O'Neill PM, Ward SA, Berry NG, Jeyadevan JP, Biagini GA, et al. (2006) A medicinal chemistry perspective on 4-aminoquinoline antimalarial drugs. Curr Top Med Chem 6: 479-507.
43. Solomon VR, Puri SK, Srivastava K, Katti SB, (2005) Design and synthesis of new antimalarial agents from 4-aminoquinoline. Bioorg Med Chem 13: 2157-2165.
44. National Research Council of the National Academies (2011) Guide for the Care and Use of Laboratory Animals. In: Institute for Laboratory Animal Research, editor. 8th ed. Washington, D.C.: The National Academies Press.
45. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J, (1999) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 179Suppl 1: S248-258.
46. Panchal RG, Kota KP, Spurgers KB, Ruthel G, Tran JP, et al. (2010) Development of high-content imaging assays for lethal viral pathogens. J Biomol Screen 15: 755-765.
47. Eli Lilly and Company and NIH Chemical Genomics Center (2008) Assay Guidance Manual Version 5.0. Available: http://www.ncgc.nih.gov/guidance/manual_toc.html.
48. Zhang J-H, Chung TDY, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.